The scientist’s investigation covers issues in Cell biology, Immunology, Integrin, Signal transduction and Vascular permeability. His Cell biology research is multidisciplinary, relying on both Endothelium and Leukocyte Rolling. His work is connected to Inflammation, Platelet, Proinflammatory cytokine, Arthritis and Lipoxin, as a part of Immunology.
His studies in Platelet integrate themes in fields like Receptor and Cell adhesion molecule. His Integrin research is multidisciplinary, incorporating perspectives in Chemokine, Molecular biology and Cell adhesion. His work carried out in the field of Vascular permeability brings together such families of science as VE-cadherin, Neutrophil extravasation and Leukocyte extravasation.
His main research concerns Cell biology, Immunology, Acute kidney injury, Inflammation and Intensive care medicine. The Cell biology study combines topics in areas such as Integrin and Cell adhesion, Leukocyte Rolling. His research integrates issues of Molecular biology and Lung injury in his study of Immunology.
His Acute kidney injury research includes elements of Cardiac surgery, Renal replacement therapy, Kidney disease and Renal function. His study looks at the relationship between Inflammation and fields such as Immune system, as well as how they intersect with chemical problems. The various areas that Alexander Zarbock examines in his Intensive care medicine study include Perioperative, Complication, MEDLINE and Anesthesiology.
Alexander Zarbock focuses on Acute kidney injury, Intensive care medicine, Renal replacement therapy, Kidney disease and Internal medicine. His Acute kidney injury study incorporates themes from Clinical trial, Kidney, Perioperative, Cardiac surgery and Dialysis. His Intensive care medicine research is multidisciplinary, incorporating elements of Complication, Disease, MEDLINE and Urine output.
His Renal replacement therapy study combines topics in areas such as Adverse effect and Gynecology. Alexander Zarbock combines subjects such as Guideline, Absolute risk reduction and Intravascular volume status with his study of Kidney disease. His research investigates the link between Area under the curve and topics such as Chemokine that cross with problems in Integrin.
Alexander Zarbock mostly deals with Acute kidney injury, Clinical trial, Renal replacement therapy, Intensive care medicine and Kidney disease. His Acute kidney injury study integrates concerns from other disciplines, such as Dialysis and Randomized controlled trial. His biological study spans a wide range of topics, including Anesthesia, Prospective cohort study, Biomarker and Cohort study.
Alexander Zarbock interconnects Guideline, Nephrology and Fluid management in the investigation of issues within Renal replacement therapy. His work deals with themes such as Disease, MEDLINE and Urine output, which intersect with Intensive care medicine. He has included themes like Renal function, Mace, Perioperative, Severity of illness and Intensive care unit in his Kidney disease study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial
Alexander Zarbock;John A. Kellum;Christoph Schmidt;Hugo Van Aken.
JAMA (2016)
Platelet-neutrophil-interactions: linking hemostasis and inflammation.
Alexander Zarbock;Alexander Zarbock;Renata K. Polanowska-Grabowska;Klaus Ley.
Blood Reviews (2007)
Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation
Alexander Zarbock;Kai Singbartl;Klaus Ley.
Journal of Clinical Investigation (2006)
Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
Melanie Meersch;Christoph Schmidt;Andreas Hoffmeier;Hugo Van Aken.
Intensive Care Medicine (2017)
GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice
Tibor Kempf;Alexander Zarbock;Christian Widera;Stefan Butz.
Nature Medicine (2011)
Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup
Lakhmir S. Chawla;Rinaldo Bellomo;Azra Bihorac;Stuart L. Goldstein.
Nature Reviews Nephrology (2017)
Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow
Alexander Zarbock;Klaus Ley;Rodger P. McEver;Andrés Hidalgo.
Blood (2011)
Neutrophils scan for activated platelets to initiate inflammation
Vinatha Sreeramkumar;José M. Adrover;Ivan Ballesteros;Maria Isabel Cuartero.
Science (2014)
Spleen Tyrosine Kinase Syk Is Necessary for E-Selectin-Induced αLβ2 Integrin-Mediated Rolling on Intercellular Adhesion Molecule-1
Alexander Zarbock;Clifford A. Lowell;Klaus Ley.
Immunity (2007)
Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial.
Alexander Zarbock;Christoph Schmidt;Hugo Van Aken;Carola Wempe.
JAMA (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
La Jolla Institute For Allergy & Immunology
University of Münster
University of Pittsburgh
Max Planck Society
Ghent University Hospital
Spanish National Centre for Cardiovascular Research
Karolinska Institute
University of Padua
Ludwig Maximilian University of Munich
University of California, San Francisco
Czech Technical University in Prague
University of Iowa
Télécom ParisTech
National University of Singapore
Nankai University
University of Manchester
Icahn School of Medicine at Mount Sinai
Indiana University
University of Miami
National University of Singapore
Michigan State University
Ottawa Hospital
Johns Hopkins University School of Medicine
European Institute of Oncology
University of Newcastle Australia
University of Hong Kong